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Defects of lipid-linked oligosaccharide assembly lead to alterations of N-linked glycosylation known as “type I
congenital disorders of glycosylation” (CDG). Dysfunctions along this stepwise assembly pathway are characterized
by intracellular accumulation of intermediate lipid-linked oligosaccharides, the detection of which contributes to
the identiﬁcation of underlying enzymatic defects. Using this approach, we have found, in a patient with CDG,
a deﬁciency of the ALG9 a1,2 mannosyltransferase enzyme, which causes an accumulation of lipid-linked-
GlcNAc2Man6 and -GlcNAc2Man8 structures, which was paralleled by the transfer of incomplete oligosaccharides
precursors to protein. A homozygous point-mutation 1567GrA (amino acid substitution E523K) was detected in
the ALG9 gene. The functional homology between the human ALG9 and Saccharomyces cerevisiae ALG9, as well
as the deleterious effect of the E523K mutation detected in the patient with CDG, were conﬁrmed by a yeast
complementation assay lacking the ALG9 gene. The ALG9 defect found in the patient with CDG—who presented
with developmental delay, hypotonia, seizures, and hepatomegaly—shows that efﬁcient lipid-linked oligosaccharide
synthesis is required for proper human development and physiology. The ALG9 defect presented here deﬁnes a
novel form of CDG named “CDG-IL.”
Glycosylation is a widespread posttranslational modiﬁ-
cation that has a considerable impact on numerous bio-
logical processes (Varki 1993). The N-linked glycosyla-
tion pathway bears the hallmark of ﬁrst assembling the
GlcNAc2Man9Glc3 oligosaccharide core on the lipid car-
rier dolichylpyrophosphate (DolPP) and then of trans-
ferring it en bloc to nascent polypeptides. In recent years,
several defects along the N-linked glycosylation pathway
have been characterized (Jaeken 2003; Thiel et al. 2003;
Wu et al. 2003; Grubenmann et al. 2004; Kranz et al.
2004; Schwarz et al. 2004) and have been deﬁned as
types of congenital disorders of glycosylation (CDG).
The majority of CDG known to date represent defects
of dolichol-linked oligosaccharide assembly, classiﬁed as
“CDG-I.”
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Clinically, CDG are associated with a broad range of
symptoms, such as the failure to thrive, axial hypotonia,
cerebellar dysfunction, seizures, mental retardation, and
coagulopathy (Krasnewich andGahl 1997). These rather
nonspeciﬁc features together with a variability in severity
of these manifestations render it difﬁcult to make a clear
diagnosis and necessitate a genetic characterization to
establish the causality of glycosylation disorders.
The study of yeast glycosylation mutants has provided
a wealth of knowledge about the mechanisms of en-
doplasmic reticulum (ER)–associated N-glycosylation
(Burda and Aebi 1999), where 120 enzymatic activities
and an even greater number of genes are involved (Freeze
2001). In addition, these yeast glycosylation mutants
have been instrumental in the characterization of several
disorders of glycosylation (Aebi and Hennet 2001). Be-
sides establishing the genetic basis of novel human dis-
eases, the identiﬁcation of additional defects along the
assembly of dolichol-linked oligosaccharides allows an
assessment of the biological importance, for humans, of
each glycosylation step.
In the present study, we report a novel type of CDG-I
identiﬁed in a female patient born at term as a twin with
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Figure 1 [3H]Mannose-labeled lipid- and N-linked oligosac-
charide proﬁles from human primary ﬁbroblasts. A, Separation of
LLOs from normal control ﬁbroblasts. B, Separation of LLOs from
patient ﬁbroblasts. C, Separation of NLOs from patient ﬁbroblasts.
Arrows mark the elution times of standard oligosaccharides from yeast
(M5–M9, GlcNAc2Man5–9; G1–G3, GlcNAc2Man9Glc1–3).
a birth weight of 2.75 kg, length of 44 cm, and head
circumference of 31.5 cm. As she grew older, her clinical
features included severe microcephaly, central hypo-
tonia, seizures, hepatomegaly, developmental delay, and
bronchial asthma. This pattern of clinical presentations
was compatible with CDG, a diagnosis conﬁrmed by iso-
electric focusing analysis of serum transferrin. The patient
sample showed signiﬁcant increase of disialo- and asialo-
transferrin, indicative of CDG-I (data not shown). Nor-
mal values of phosphomannomutase activity measured in
patient ﬁbroblast extracts excluded the most frequent
CDG type, CDG-Ia (MIM 212065). To detect a possible
defect of lipid-linked oligosaccharide (LLO) assembly, ﬁ-
broblasts from the patient were labeled with [3H]man-
nose, and the glycans released from the lipid carrier or
cleaved from proteins were analyzed by high-performance
liquid chromatography, as described elsewhere (Gruben-
mann et al. 2002). The LLO proﬁle revealed an accu-
mulation of incomplete precursor structures correspond-
ing to DolPP-GlcNAc2Man6 and DolPP-GlcNAc2Man8
(ﬁg. 1B). In comparison, only the complete DolPP-
GlcNAc2Man9Glc3 LLO is found in healthy control ﬁ-
broblasts (ﬁg. 1A).
The analysis of protein N-linked oligosaccharides
(NLO) conﬁrmed the glycosylation alteration detected
in the patient’s ﬁbroblasts. The normal NLO proﬁle of
human ﬁbroblasts corresponds to three peaks repre-
senting the structures GlcNAc2Man8, GlcNAc2Man9,
and GlcNAc2Man9Glc1 (data not shown). GlcNAc2Man9
and GlcNAc2Man8 arise from the immediate trimming
of NLO by ER resident glucosidase and a-mannosidase
enzymes (Kilker et al. 1981; Camirand et al. 1991). In
the patient with CDG, an additional peak possibly cor-
responding to the incomplete GlcNAc2Man6 structure
was visible (ﬁg. 1C), suggesting that truncated oligosac-
charides were transferred to proteins in this patient.
The dual accumulation of DolPP-GlcNAc2Man6 and
DolPP-GlcNAc2Man8 suggested a possible defect at the
level of the ALG9 a1,2-mannosyltransferase, which, in
yeast, catalyzes the addition of the seventh (Burda et al.
1996) and ninth (C. G. Frank and M. Aebi, unpublished
data) mannose residues on growing LLOs (ﬁg. 2). A hu-
man homolog to the yeast ALG9 gene (MIM 606941)
has been described recently (Entrez accession number
AF395532) (Baysal et al. 2002). The cDNA encodes a
predicted multispanning membrane protein of 611 amino
acids, with 43% similarity to the Saccharomyces cerevi-
siae Alg9 protein. A sequence alignment of several Alg9
proteins showed highly conserved domains, possibly rep-
resenting regions responsible for the active site of this
enzyme (ﬁg. 3). The human ALG9 cDNA was prepared
from 4 mg of total ﬁbroblast RNA by use of the speciﬁc
reverse-transcription primer 5′-TGTTACAGGCGATG-
ACTTGC-3′. The protein-coding region of the ALG9
cDNA was ampliﬁed by PCR with 3 ml of reverse tran-
scription product and the primers 5′-CGCGCTCACC-
GACTTCATA-3′ and 5′-GGAGTCAGGTCACTGGA-
ATCA-3′ through 30 cycles of ampliﬁcation at 94C for
45 s, at 53C for 30 s, and at 72C for 90 s. The PCR
fragments were sequenced directly. In the patient ALG9
cDNA, we detected the point mutation 1567GrA,
which introduced the amino acid change E523K in the
ALG9 protein (ﬁg. 3). This mutation was not found in
the control cDNA samples that were sequenced nor in
108 expressed sequence tags retrieved from GenBank,
excluding the possibility of a frequently occurring poly-
morphism. As a conﬁrmation, the 1567GrA mutation
was also detected at the genomic level by sequencing
exon 14 of the patient ALG9 gene (data not shown).
To verify that the E523K mutation impaired ALG9
function, we analyzed the mutant human cDNA in a
yeast complementation assay. Deletion of ALG9 alone
in yeast does not result in any obvious growth pheno-
type. We therefore used the synthetic phenotype of a
Dalg9 wbp1-2 double mutant. The combination of the
deﬁciency in LLO biosynthesis (Dalg9) and a reduced
Figure 2 LLO biosynthesis pathway in the ER lumen. Arrows mark the reactions in which dolichol-phosphate (DolP)–Man or DolP-Glc
are used as substrates and where the DolP-Man–dependent transferases ALG3, ALG9, and ALG12 are involved. The complete oligosaccharide
GlcNAc2Man9Glc3 is transferred from its lipid carrier to nascent polypeptides by the oligosaccharyltransferase complex (OST). Known types
of CDG are marked with the respective names CDG-Ic, -Id, -Ig, and -Ih.
Figure 3 ALG9 protein sequence comparison. Amino acid sequences of ALG9 proteins from Homo sapiens (Hs) (Entrez accession number
AAL25798), Caenorhabditis elegans (Ce) (Entrez accession number CAA90107), Drosophila melanogaster (Dm) (Entrez accession number
NP_651353), Schizosaccharomyces pombe (Sp) (Entrez accession number CAB75773), and S. cerevisiae (Sc) (Entrez accession number
CAA96122) were aligned using the ClustalW program (Thompson et al. 1994). The amino acid change E523K is indicated for the human
ALG9 protein.
Reports 149
Figure 4 Complementation of Dalg9 wbp1-2 yeasts with human ALG9 cDNAs. Transformants were spotted in sixfold dilutions on YPD
plates and were incubated at 23C, at 30C, or at 33C for 120 h. Transformants carried either the vector alone (“mock”), a plasmid comple-
menting the wbp1-2 mutation (“WBP1”), the pALG9 plasmid expressing the S. cerevisiae ALG9 gene (“ScALG9”), or plasmids expressing
the normal human ALG9 cDNA or the CDG patient ALG9[E523K] cDNA.
oligosaccharyltransferase activity (wbp1-2) results in a
temperature-sensitive phenotype at 30C (Burda et al.
1996). The Dalg9 wbp1-2 strain was transformed with
control plasmids and multicopy plasmids expressing
the normal human ALG9 or the ALG9[E523K] cDNAs,
under control of the strong TDH3 promoter. The hu-
man ALG9 cDNA included the common polymorphism
865GrA described elsewhere (Baysal et al. 2002). In
contrast to the human wild-type ALG9 cDNA, trans-
formation of the mutant ALG9[E523K] allele showed
only a minor effect on growth of Dalg9 wbp1-2 yeasts
at 33C (ﬁg. 4). Both versions restored growth at 30C,
indicating a residual activity of ALG9[E523K]. This
demonstrates that human ALG9 is functionally homol-
ogous to yeast ALG9 and that the E523K mutation has
a detrimental effect on ALG9 function. When the bio-
chemical phenotype of the CDG ﬁbroblasts is consid-
ered, this study demonstrates that the humanALG9 pro-
tein catalyzes, like its yeast counterpart, the transfer of
mannose onto the two acceptor substrates DolPP-
GlcNAc2Man6 and DolPP-GlcNAc2Man8.
Clinically, the ALG9 deﬁciency was accompanied by
symptoms that are common for most types of CDG-I;
that is, developmental delay, hypotonia, and epilepsy.
The fact that a signiﬁcant residual ALG9 activity was
detected, as shown by the presence of normal NLOs in
the cells of the patient with CDG and by the yeast com-
plementation assay, underlines the importance of the re-
actions catalyzed by ALG9, since even a leaky mutation
accounts for a severe disease phenotype. As for all types
of CDG-I, the disease is caused by protein underglyco-
sylation; that is, the nonoccupancy of critical N-glyco-
sylation sites, which probably accounts for most of the
clinical manifestations observed. However, transfer of
truncated oligosaccharides to protein may also affect
intracellular processes of glycoproteins, such as the chap-
erone-assisted protein folding, degradation of malfolded
proteins in the ER (ERAD), the ER-Golgi trafﬁcking,
and the transport to lysosomes (Plemper andWolf 1999;
Parodi 2000; Helenius and Aebi 2001). The monogluco-
sylation of N-glycans, reciprocally controlled by gluco-
sidase II and the UDP-Glc:glycoprotein glucosyltransfer-
ase (GT), regulates the association of glycoproteins with
chaperone lectins in the so-called calnexin/calreticulin
cycle (Parodi 2000; Helenius and Aebi 2001). In vitro
studies showed that truncated N-glycan structures with
!9 mannoses are suboptimal substrates for GT (Sousa et
al. 1992) or for the lectin chaperones calreticulin and
calnexin (Ware et al. 1995; Spiro et al. 1996). Sugar
structures also control glycoprotein degradation. For ex-
ample, in ALG9-null yeast mutants, ERAD of a mal-
folded glycoprotein was impaired (Jakob et al. 1998).
Therefore, part of the phenotype for patients with CDG
could result from transfer of shorter-than-normal gly-
cans to protein, which might interfere with cellular pro-
tein quality-control mechanisms.
The neurological symptoms found in most types of
CDG demonstrate the importance of N-glycosylation for
development and function of the nervous system (Kras-
newich and Gahl 1997; Jaeken and Matthijs 2001). Re-
cently, Baysal et al. (2002) found carriers of a chromo-
some translocation interrupting the ALG9 gene in a
family showing a high frequency of bipolar affective dis-
order (BPAD [MIM 125480]). It could be speculated that
ALG9 activity, required at two steps along the pathway,
becomes rate limiting in cells if only one productive copy
of the gene is present. Similarly, mild neurological al-
terations and behavioral disorders have been described
among mild cases of CDG-Ia (Gru¨newald et al. 2001;
Briones et al. 2002). Although involvement of theALG9
mannosyltransferase activity in BPAD requires further
study, it may be relevant to consider testing for altera-
tions of N-glycosylation in patients with BPADor related
psychiatric diseases.
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